My Question: "I challenge you to find a Biotech on the ASX which represents better value than CUV."
Your Answer: "ROTFL. Most Companies are listed on the ASX because they can't find anyone to buy their worthless technology. The only thing CUV has actually achieved is getting orphan drug status for a 40 year old drug after 15 years of effort. If you knew anything about the drug approval process you would know orphan drug status isn't hard to obtain."
Now your answer is truly funny - every single sentence is totally WRONG! That means you either have no clue about what's going on in the world or you are deliberately trying to distort. Which one? I'm just going to focus on one wrong sentence that the only thing CUV has achieved is "getting orphan drug status". Wrong. That was a long time ago when at the start of seeking approval for their drug. Do you actually realise Clinuvel has since achieved FDA approval for their drug? Along with TGA, EMA and Israel approvals. They are at the early stages of commercial sales and have been making great profits for several years just on an Orphan indication and they are now branching the SAME drug into blockbuster indications like STROKE and DNA REPAIR and VITILIGO. Also massive growing cash reserves and an unheard of dividend for a company just doing sales on an orphan indication and about to branch into OTCs. Now I will repeat my question which you blatantly avoided "I challenge you to find a Biotech on the ASX which represents better value than CUV." Virtually none have FDA approval and even less can boast such powerful financial fundamentals as CUV or even anything close to that.
All IMO DYOR
- Forums
- ASX - By Stock
- CUV
- Ann: Media release - First stroke patient with afamelanotide
Ann: Media release - First stroke patient with afamelanotide, page-28
-
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
STX
Strike hands $48.5M contract to Clarke Energy to produce 20x 4.5MW gas engines for Sth Erregulla
AVH
Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.68 |
Change
-0.240(1.61%) |
Mkt cap ! $735.1M |
Open | High | Low | Value | Volume |
$14.75 | $14.92 | $14.65 | $503.5K | 34.18K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 448 | $14.68 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.74 | 149 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 448 | 14.680 |
1 | 340 | 14.600 |
2 | 1069 | 14.560 |
1 | 2000 | 14.520 |
1 | 500 | 14.500 |
Price($) | Vol. | No. |
---|---|---|
14.980 | 1000 | 1 |
15.150 | 519 | 1 |
15.180 | 100 | 1 |
15.190 | 50 | 1 |
15.200 | 47 | 1 |
Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |